Double Approval Boost For Dova’s Doptelet But EU Licensee Still Sought

A first approval in the EU and an expanded US label for Dova’s TPO product should alter the its sales trajectory – all it needs now is an EU partner.

Eggs_Bacon
Double reason to smile for Dova • Source: Shutterstock

Two new approvals have given a fillip to Dova Pharmaceuticals Inc.’s oral thrombopoietin receptor agonist Doptelet (avatrombopag). The European Medicines Agency has approved it for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure, a decision that came just two days before the US Food and Drug Administration expanded the product’s US label to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

The market for ITP is bigger and more established that that for CLD patients, Dova noted, and the new label...

Welcome to Scrip

Create an account to read this article

More from New Products

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.